TWI590826B - 含短效性苯二氮平之組成物 - Google Patents

含短效性苯二氮平之組成物 Download PDF

Info

Publication number
TWI590826B
TWI590826B TW102118175A TW102118175A TWI590826B TW I590826 B TWI590826 B TW I590826B TW 102118175 A TW102118175 A TW 102118175A TW 102118175 A TW102118175 A TW 102118175A TW I590826 B TWI590826 B TW I590826B
Authority
TW
Taiwan
Prior art keywords
composition
freeze
dried
cns
group
Prior art date
Application number
TW102118175A
Other languages
English (en)
Chinese (zh)
Other versions
TW201400119A (zh
Inventor
約翰 艾肯 葛拉罕
亞倫 詹姆士 貝利
凱文 李察 沃德
湯瑪斯 皮卡克
Original Assignee
寶恩英國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48669863&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI590826(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 寶恩英國公司 filed Critical 寶恩英國公司
Publication of TW201400119A publication Critical patent/TW201400119A/zh
Application granted granted Critical
Publication of TWI590826B publication Critical patent/TWI590826B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW102118175A 2012-05-22 2013-05-22 含短效性苯二氮平之組成物 TWI590826B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12168968 2012-05-22

Publications (2)

Publication Number Publication Date
TW201400119A TW201400119A (zh) 2014-01-01
TWI590826B true TWI590826B (zh) 2017-07-11

Family

ID=48669863

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102118175A TWI590826B (zh) 2012-05-22 2013-05-22 含短效性苯二氮平之組成物

Country Status (41)

Country Link
US (2) US20150148338A1 (enExample)
EP (1) EP2852389B1 (enExample)
JP (1) JP6313286B2 (enExample)
KR (1) KR102116737B1 (enExample)
CN (2) CN104968348B (enExample)
AP (1) AP2014008084A0 (enExample)
AR (1) AR092008A1 (enExample)
AU (1) AU2013265295B2 (enExample)
BR (1) BR112014029108B1 (enExample)
CA (1) CA2874247C (enExample)
CL (1) CL2014003171A1 (enExample)
CO (1) CO7151503A2 (enExample)
DK (1) DK2852389T3 (enExample)
EA (1) EA032119B1 (enExample)
EC (1) ECSP14032553A (enExample)
ES (1) ES2651389T3 (enExample)
FR (1) FR21C1043I2 (enExample)
GE (1) GEP20186852B (enExample)
HR (1) HRP20171872T1 (enExample)
HU (2) HUE037734T2 (enExample)
IL (1) IL235789B (enExample)
LT (2) LT2852389T (enExample)
LU (1) LUC00230I2 (enExample)
MA (1) MA37581B1 (enExample)
MX (1) MX368854B (enExample)
MY (1) MY185117A (enExample)
NL (1) NL301130I2 (enExample)
NO (2) NO2852389T3 (enExample)
NZ (1) NZ702063A (enExample)
PE (1) PE20150683A1 (enExample)
PH (1) PH12014502608B1 (enExample)
PL (1) PL2852389T4 (enExample)
PT (1) PT2852389T (enExample)
RS (1) RS56660B1 (enExample)
SG (1) SG11201407710VA (enExample)
SI (1) SI2852389T1 (enExample)
TN (1) TN2014000479A1 (enExample)
TW (1) TWI590826B (enExample)
UA (1) UA115063C2 (enExample)
WO (1) WO2013174883A1 (enExample)
ZA (1) ZA201408412B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007071A1 (en) 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
EP2305647A1 (en) 2009-09-18 2011-04-06 PAION UK Limited Process for preparing 3-[(4S)-8-bromo-1-methyl-6-(2-pyridinyl)-4 H-imidazo[1,2-a][1,4]benzodiazepine-4-yl] propionic acid methyl ester or the benzene sulfonate salt thereof, and compounds useful in that process
EP2450039A1 (en) 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
WO2015076340A1 (ja) * 2013-11-21 2015-05-28 小野薬品工業株式会社 全身麻酔および/または鎮静のための注射用組成物
EP3106004B1 (en) 2014-02-10 2023-07-19 Biolumic Limited Improvements in and relating to controlling characteristics of photosynthetic organisms
EP3116296B1 (en) 2014-03-14 2020-05-06 Biolumic Limited Method to improve crop yield and/or stress resistance
WO2016011943A1 (zh) * 2014-07-23 2016-01-28 李勤耕 新的苯并二氮杂䓬类衍生物及其用途
MX387212B (es) 2014-09-17 2025-03-18 Biolumic Ltd Métodos para tratamiento de semillas y productos resultantes.
CN105726495B (zh) * 2014-12-12 2019-03-29 宜昌人福药业有限责任公司 一种注射用短效苯并二氮杂卓盐药物组合物及其制备方法
CN107198691A (zh) * 2016-03-17 2017-09-26 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
MX2018012498A (es) 2016-04-14 2019-07-01 Paion Uk Ltd Benzodiazepinas inhaladas y nasales oralmente.
CN108289897B (zh) * 2016-05-20 2020-07-28 江苏恒瑞医药股份有限公司 一种瑞马唑仑的药物组合物
US11147221B2 (en) 2016-08-22 2021-10-19 Biolumic Limited Methods of seed treatment and resulting products
CN108503644B (zh) 2016-12-09 2019-06-14 成都倍特药业有限公司 一种苯并二氮杂*衍生物的氢溴酸盐及其制备方法和用途
JP2020525002A (ja) 2017-06-29 2020-08-27 バイオルミック リミテッド 作物の収量および/あるいは品質を改善する方法
EP3714884A1 (en) 2019-03-27 2020-09-30 Paion UK Limited Medical uses for benzodiazepines with a particular eeg pattern
CN112209932B (zh) * 2019-07-12 2023-03-24 成都倍特药业股份有限公司 一种化合物氢溴酸盐的新固体形态及其制备方法和用途
ES2803099B2 (es) 2019-07-22 2021-11-08 Moehs Iberica Sl Procedimiento de obtención de besilato de remimazolam amorfo
CN114478535B (zh) * 2020-10-23 2024-02-09 成都苑东生物制药股份有限公司 一种苯磺酸瑞马唑仑ii晶型的制备方法
CN112462015B (zh) * 2020-11-18 2022-07-12 海南倍特药业有限公司 一种氢溴酸瑞马唑仑细菌内毒素的检测方法
CN114624351B (zh) * 2020-12-14 2024-04-09 宜昌人福药业有限责任公司 苯磺酸瑞马唑仑原料药中(r)-(-)-1-氨基-2-丙醇残留的分析方法
AU2023394304A1 (en) * 2022-12-16 2025-05-22 Lts Lohmann Therapie-Systeme Ag Oromucosal delivery system containing remimazolam
WO2024251275A1 (zh) * 2023-06-09 2024-12-12 成都麻沸散医药科技有限公司 一种氮杂*类化合物及其组合物和应用
WO2025052259A1 (en) 2023-09-05 2025-03-13 Reena Patel Ready to use compositions of remimazolam

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3520877A (en) 1967-10-02 1970-07-21 Hoffmann La Roche 3-carbonyl amino acetic acid ethyl ester substituted benzodiazepines
CA2143246C (en) 1994-03-16 2000-08-22 Thierry Godel Imidazodiazepines
AU4296196A (en) 1995-01-06 1996-07-24 F. Hoffmann-La Roche Ag Hydroxymethylimidazodiazepines and their esters
AU4382896A (en) 1995-02-02 1996-08-21 F. Hoffmann-La Roche Ag Acetylimidazobenzodiazepines
JPH0971533A (ja) * 1995-06-30 1997-03-18 Takeda Chem Ind Ltd 凍結乾燥製剤
GB9911152D0 (en) * 1999-05-14 1999-07-14 Glaxo Group Ltd Short-acting benzodiazepines
US7160880B1 (en) * 1999-05-14 2007-01-09 Cenes Limited Short-acting benzodiazepines
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
EP1161949A1 (en) * 2000-06-09 2001-12-12 Warner-Lambert Company Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease
EP1853234A2 (en) * 2005-02-15 2007-11-14 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
GB0613693D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts (3)
GB0613692D0 (en) * 2006-07-10 2006-08-16 Cenes Ltd Benzodiazepine salts
WO2008007071A1 (en) * 2006-07-10 2008-01-17 Cenes Limited Short-acting benzodiazepine salts and their polymorphic forms
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
SI2496582T1 (sl) * 2009-11-05 2016-04-29 Glaxosmithkline Llc Corporation Service Company Benzodiazepinski inhibitor bromodomene
EP2450039A1 (en) * 2010-11-08 2012-05-09 PAION UK Ltd. Dosing regimen for sedation with CNS 7056 (Remimazolam)
CN102964349A (zh) 2011-08-31 2013-03-13 江苏恒瑞医药股份有限公司 苯并二氮杂*衍生物的托西酸盐及其多晶型、它们的制备方法和用途

Also Published As

Publication number Publication date
IL235789A0 (en) 2015-01-29
WO2013174883A1 (en) 2013-11-28
NL301130I1 (enExample) 2021-09-22
EA032119B1 (ru) 2019-04-30
ZA201408412B (en) 2016-09-28
PH12014502608A1 (en) 2015-01-21
CA2874247A1 (en) 2013-11-28
FR21C1043I1 (enExample) 2021-11-19
PL2852389T4 (pl) 2022-02-21
PE20150683A1 (es) 2015-06-03
LT2852389T (lt) 2017-12-27
NO2852389T3 (enExample) 2018-03-17
SI2852389T1 (en) 2018-02-28
AU2013265295A1 (en) 2015-01-22
CN104968348A (zh) 2015-10-07
TN2014000479A1 (en) 2016-03-30
MX2014014225A (es) 2015-06-17
IL235789B (en) 2019-07-31
AP2014008084A0 (en) 2014-11-30
ECSP14032553A (es) 2018-11-30
CO7151503A2 (es) 2014-12-29
CN104968348B (zh) 2018-04-17
CN108578413A (zh) 2018-09-28
PH12014502608B1 (en) 2019-11-27
PT2852389T (pt) 2017-12-13
TW201400119A (zh) 2014-01-01
FR21C1043I2 (fr) 2022-10-07
EA201492160A1 (ru) 2015-10-30
US20150148338A1 (en) 2015-05-28
PL2852389T3 (pl) 2018-02-28
MX368854B (es) 2019-10-18
NL301130I2 (nl) 2021-10-25
KR20150009601A (ko) 2015-01-26
UA115063C2 (uk) 2017-09-11
GEP20186852B (en) 2018-05-25
LTPA2021521I1 (enExample) 2021-10-11
RS56660B1 (sr) 2018-03-30
KR102116737B1 (ko) 2020-05-29
MA37581B1 (fr) 2016-07-29
SG11201407710VA (en) 2015-01-29
EP2852389B1 (en) 2017-10-18
BR112014029108A2 (pt) 2017-06-27
BR112014029108B1 (pt) 2022-02-08
CL2014003171A1 (es) 2015-06-19
HUE037734T2 (hu) 2018-09-28
MA20150233A1 (fr) 2015-07-31
HUS2100040I1 (hu) 2021-10-28
HRP20171872T1 (hr) 2018-02-23
HK1208164A1 (en) 2016-02-26
AU2013265295B2 (en) 2017-08-31
JP2015517552A (ja) 2015-06-22
NZ702063A (en) 2016-11-25
JP6313286B2 (ja) 2018-04-18
US20220040198A1 (en) 2022-02-10
EP2852389A1 (en) 2015-04-01
MY185117A (en) 2021-04-30
AR092008A1 (es) 2015-03-18
NO2021041I1 (no) 2021-09-20
CA2874247C (en) 2020-07-28
LUC00230I2 (enExample) 2022-10-07
ES2651389T3 (es) 2018-01-26
LTC2852389I2 (enExample) 2024-11-25
DK2852389T3 (en) 2017-12-18

Similar Documents

Publication Publication Date Title
TWI590826B (zh) 含短效性苯二氮平之組成物
JP5536753B2 (ja) ベンダムスチン塩酸塩の新規固体形態
EP3178817B1 (en) Amorphous form of tetracyclic compound
BR112014013332B1 (pt) Composições farmacêuticas de 7-(6-(2-hidroxi-propan-2-il)piridin-3-il)-1-((trans)-4- metoxicicloexil)-3,4-diidropirazino [2,3-b]pirazin-2(1h)-ona, uma forma sólida dessa e métodos de seu uso
EP3127909A1 (en) Crystalline forms of rifaximin and their preparation in the presence of amino acids
EP3274332B1 (en) Crystalline forms of cabozantinib phosphate and cabozantinib hydrochloride
US9534004B2 (en) Crystalline forms of ceftaroline fosamil
TW201143761A (en) Tablet formulation of ezatiostat
US9308174B2 (en) Lyophilized formulations of bendamustine hydrochloride
EP3856151B1 (en) Lyophilisate of treosulfan
CN103724359B (zh) 一种无定形头孢替坦酸及由其制备头孢替坦二钠的方法和含有该头孢替坦二钠的药物组合物
HK1208164B (en) Compositions comprising short-acting benzodiazepines
HK40048001B (en) Lyophilisate of treosulfan
HK40048001A (en) Lyophilisate of treosulfan
CN111100122A (zh) 左旋四氢帕马丁新化合物
OA20108A (en) Compositions Comprising Short-Acting Benzodiazepines.